{"entity":{"id":"nct06419179","kind":"trial","name":"Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extens","aka":["GUIDANCE"],"tldr":"A phase 2 trial of durvalumab and olaparib in lung cancer, run by University of Cologne, now recruiting.","summary":"Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) is a phase 2, interventional study registered as NCT06419179 by University of Cologne, with a registry enrolment figure of 29 participants, started 2024-10-09 and due to reach its primary completion in 2026-09. Interventions recorded: Durvalumab; Olaparib. Conditions listed: Small Cell Lung Carcinoma. Primary outcome: Progression-free survival (PFS). Lung eligibility wording from the registry: \"* Newly diagnosed, histologically documented advanced or metastatic small-cell lung cancer (UICC stage III which is not amenable to curative radiochemotherapy or stage IV)\". Sites: Germany. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06419179","url":"https://clinicaltrials.gov/study/NCT06419179"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["sclc"],"sections":[],"technologies":["checkpoint-inhibitor","parp-inhibitor"],"targets":[],"drugs":["durvalumab","olaparib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06419179","phase":"2","setting":"A Multicenter Phase II Trial of Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in Homologous Recombination Deficiency (HRD) Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)","sponsor":"University of Cologne","enrolled":29,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06419179/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}